Market Place
Sourcing Support
Dr. Paulo Fontoura Joins STALICLA As Development Advisor
19 Sep 2024 //
GLOBENEWSWIRE
STALICLA appoints Dr. Purnanand Sarma, PhD, as Chair of the Board of Directors
09 Jul 2024 //
GLOBENEWSWIRE
STALICLA publishes pioneering phase 1b data on precision treatment
27 Jun 2024 //
GLOBENEWSWIRE
STALICLA Initiates US DDI Study Of STP7 For Cocaine Use Disorder
02 May 2024 //
GLOBENEWSWIRE
STALICLA Appoints Dr. Thomas Blaettler, MD
11 Apr 2024 //
BUSINESSWIRE
Stalicla Secures $17.4 Million in Series B Financing
16 Jan 2024 //
GLOBENEWSWIRE
STALICLA and Firefly enter Partnership Agreement for the Development of EEG
27 Mar 2023 //
GLOBENEWSWIRE
STALICLA signs CRADA with US NIDA to cover PIII development of mavoglurant
08 Mar 2023 //
GLOBENEWSWIRE
STALICLA signs in-licensing agreement for late-stage clinical neuropsychiatric
09 Jan 2023 //
GLOBENEWSWIRE
Stalicla pledges $270M for Novartis` failed fragile X asset
09 Jan 2023 //
FIERCE BIOTECH
STALICLA to in-license SFX-01 from Evgen for neurodevelopment disorder
10 Oct 2022 //
FIRSTWORLDPHARMA
STALICLA Nabs EUR 1.7M to Lead Computational Drug in EU-funded REPO4EU Project
19 Jul 2022 //
BUSINESSWIRE
STALICLA Completes Successful Phase 1b Trials in Autism Spectrum Disorder
24 Mar 2022 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.